BioCryst Pharmaceuticals, Inc. (BCRX) Stock: A Strong Pick In The Biotech Space?

0

BioCryst Pharmaceuticals, Inc. (BCRX) is falling in the market today. The stock, one that is focused on the biotechnology industry, is currently priced at $1.79 after a move down of -6.28% so far in today’s session. When it comes to biotechnology stocks, there are a number of factors that have the potential to generate declines in the market. News is one of the most common reasons for movement. Here are the most recent headlines relating to BCRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-12-19 04:01PM BioCryst Commences Public Offering of Common Stock
Nov-11-19 07:45AM Imagine Owning BioCryst Pharmaceuticals (NASDAQ:BCRX) And Trying To Stomach The 80% Share Price Drop
Nov-07-19 07:00AM Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
Nov-06-19 08:25AM BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
07:36AM Triangle pharma inks $44M Japanese deal for new drug

However, when making an investing decision, prospective investors should focus on far more than just news, this is especially the case in the generally speculative biotech space. Here’s what’s going on with BioCryst Pharmaceuticals, Inc..

Trends That We’ve Seen From BCRX

Although a decline in a single session, like what we’re seeing from BioCryst Pharmaceuticals, Inc. might lead to fear in some investors, a single session decline by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally important to look at trends for a period longer than a single trading day. As it relates to BCRX, here are the returns that we’ve seen:

  • Past 7 Days – In the past week, BCRX has generated a price change in the amount of -11.82%.
  • Monthly – The return from BioCryst Pharmaceuticals, Inc. over the last month has been -25.10%.
  • Past Three Months – Over the past three months, the stock has produced a return that comes to -33.70%
  • Bi-Annually – Over the last six months, investors have seen a change of -77.40% from the company.
  • Year To Date – Since the the first trading session of this year BCRX has produced a return on investment of -77.82%.
  • Annually – Lastly, throughout the last year, we’ve seen movement that comes to -76.75% from BCRX. In this period of time, the stock has traded at a high of -82.01% and a low price of -5.79%.

Key Ratios

Digging into various key ratios associated with a stock can give traders an understanding of just how dangerous and/or rewarding a stock pick may be. Below are a few of the important ratios to consider when looking at BCRX.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this ratio, the more investors believe that the price of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the space. Nonetheless, in relation to BioCryst Pharmaceuticals, Inc., it’s short ratio is 9.68.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Basically, they measure whether or not a company can pay for its debts as they mature based on quick assets or current assets. In the biotechnology sector, many companies are heavily reliant on continued support from investors, the current and quick ratios can look bad. However, quite a few gems in the biotech sector come with great current and quick ratios. As far as BCRX, the quick and current ratios total up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. In this case, that ratio is -0.08.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology sector, this is a very important ratio to consider. When it comes to BCRX, the cash to share value works out to 0.82.

Analyst Opinions Of BioCryst Pharmaceuticals, Inc.

While it’s not a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their thoughts to validate your own thoughts when it comes to making investment decisions in the biotech sector. Here are the recent moves that we have seen from analysts with regard to BCRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-24-19 Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18 Resumed Piper Jaffray Overweight $15
Aug-08-18 Resumed JP Morgan Overweight $9
Jul-17-18 Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18 Initiated Seaport Global Securities Neutral

What Institutions And Insiders Think Of BioCryst Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BCRX, here’s what we’re seeing:

  • Institutions – Currently, institutions own 95.00% of BCRX. On the other hand, it’s worth considering that institutional ownership has seen a move of 2.47% over the past 3 months.
  • Insider Moves – with regard to insiders, members of the management team and others close to BCRX currently hold 0.20% of BioCryst Pharmaceuticals, Inc.. Insider ownership of the company has seen a move of -14.50% throughout the last 3 months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 112.07M shares of BioCryst Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, BCRX has a float of 109.30M.

I also find it important to pay attention to the short percentage of the float. Think about it, if a large portion of the float available for trading is sold short, the overall opinion in the market is that the stock is headed for a deep dive. With regard to BCRX, the percentage of the float that is currently being sold short is 12.75%. Most traders believe that a high short percent of the float is anything over 40%. In my research, I’ve seen that any short percent of the float over 26% is likely a play that comes with hefty risk.

What We’ve Seen In Financial Results

What have ween seen from BCRX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that BioCryst Pharmaceuticals, Inc. will create EPS that comes to -1.03, with -0.29 being reported in the earnings report for the current quarter. Although this isn’t earnings driven, because we are talking about analysts, BCRX is presently graded as a 2.30 considering a scale that ranges from 1 to 5 on which 1 is the worst average Wall St. analyst rating and 5 is the best.
  • 5-Year Sales – Throughout the past 5 years, BioCryst Pharmaceuticals, Inc. has reported a change in sales that comes to a total of 3.60%. Earnings per diluted share over the past half decade have seen a change of -12.50%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is often referred to as in the world of humans, BCRX has experienced a earnings change by -82.60%. BCRX has also moved the needle when it comes to revenue in the amount of -88.80%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I’m incredibly dependent on human beings. After all, humans built me! Although, my builders enabled me to learn, it’s quite a bit simpler to do so when I receive feedback from humans. Below this content, you will see a comment section. If you would like for me consider other data, evolve the way provide data, comprehend information from an alternative perspective, or you’re interested in telling me anything else, I’d love to learn. To let me in on your thoughts leave a comment below. I will read your comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here